Billions are rolling into the Justice Department off Big Pharma's fraud settlements. But, as The New York Times reminds us today, federal prosecutorrs have so far failed to prosecute more than a handful of company executives for breaking the rules.
Pfizer and Johnson & Johnson have admitted defeat on intravenous bapineuzumab.
Just as Johnson & Johnson is wrapping up its long-running Risperdal marketing investigation, the feds are eyeing its promotions for another drug: its antibiotic Doribax. The U.S. Justice Department demaded Doribax marketing information in April, J&J disclosed in its latest filing with the Securities and Exchange commission.
Keppra (levetiracetam) gained approval 13 years ago as a treatment for epilepsy. But just as many drugs end up having unexpected uses in other indications, Keppra could also help treat some patients suffering from Alzheimer's disease, researchers from the Gladstone Institutes in San Francisco believe.
Pfizer and Johnson & Johnson have nixed development of one of the most closely watched drugs in their pipelines, bapineuzumab, after two Phase III clinical trials for the experimental Alzheimer's therapy ended in failure.
Has Teva Pharmaceutical Industries ($TEVA) been paying la mordida in Latin America? The U.S. government wants to know. The Securities and Exchange Commission issued a subpoena to the Israeli company, asking for documents from its operations south of the border, as part of a long-standing government bribery probe.
Johnson & Johnson has come through with more of its cancer drug Doxil to fill orders from biotechs that need the drug for their clinical trials, after months of rationing the drug because of a key supplier's manufacturing problems.
Buried deep in Thursday's quarterly report filing is Johnson & Johnson's ($JNJ) acknowledgement that it has an agreement to settle criminal cases brought by the Department of Justice and some states over its overly aggressive marketing of its antipsychotic, Risperdal, and a few other matters.
Manufacturing problems at a Boehringer Ingelheim plant did a double whammy on Johnson & Johnson's ($JNJ) cancer drug, Doxil. It forced J&J to ration the drug to patients, current and future. It also interrupted clinical trials testing new drugs with or against J&J's ovarian cancer treatment putting pipelines in jeopardy.
Dendreon ($DNDN) CEO John Johnson says the company is setting a new course to profitability. It just doesn't include its New Jersey manufacturing plant and 600 employees company wide.